TRACON Pharmaceuticals Inc. | Ownership
Companies that own TRACON Pharmaceuticals Inc.
Puissance Capital Management LP
4,601,768
15.42%
1,238,937
6.1%
06/30/2018
Linden Advisors LP
2,842,477
9.52%
0
0.19%
06/30/2018
683 Capital Management LLC
2,738,938
9.18%
1,238,938
0.66%
06/30/2018
Renaissance Technologies LLC
719,900
2.41%
208,300
0%
06/30/2018
The Vanguard Group, Inc.
671,786
2.25%
397,662
0%
06/30/2018
Telemetry Investments LLC
451,607
1.51%
451,607
1.12%
06/30/2018
Brookline Investments, Inc.
384,333
1.29%
0
100%
04/06/2018
New York Life Investment Management LLC
143,000
0.48%
0
0%
06/30/2018
Candriam Belgium SA
143,000
0.48%
0
0%
07/31/2018
JPMorgan Securities LLC (Investment Management)
111,924
0.38%
71,900
0%
06/30/2018
| Address |
4350 La Jolla Village Drive
San Diego California 92122
United States
|
|
Employees
|
- |
| Website |
http://www.traconpharma.com |
| Updated |
07/08/2019 |
| TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company products include TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, TRC205 an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. |
